ICH E6(R2) (Good Clinical Practice, 2016 Addendum)

ICH E6(R2) is the 2016 addendum to the International Council for Harmonisation’s core Good Clinical Practice (GCP) guideline, ICH E6(R1) (1996). Adopted by the FDA as final guidance on 1 March 2018, it added Section 5.0 (Quality Management) and revised Section 5.18 (Monitoring), and remains operative for trials not yet transitioned to ICH E6(R3).

What the 2016 addendum actually changed

E6(R1) (1996) already set out the foundational GCP principles — informed consent, IRB/independent ethics committee oversight, investigator and sponsor responsibilities, essential documents — that E6(R2) leaves untouched. The addendum’s own stated purpose was to encourage more efficient, technology-enabled approaches to trial conduct and oversight without weakening participant protection or data reliability. Concretely, it:

• Added Section 5.0, Quality Management, requiring sponsors to implement a quality management system covering the trial design, data collection, and reporting processes, and to identify risks to critical trial processes and data at both the system level and the trial level (a risk-based, quality-by-design approach, rather than applying maximal control uniformly to every process regardless of actual risk).
• Introduced quality tolerance limits (QTLs) under Section 5.0.4 — predefined thresholds for a small number of trial-critical parameters, where a breach triggers a documented root-cause evaluation and, where needed, corrective and preventive action.
• Revised Section 5.18 (Monitoring) to formally recognize monitoring approaches beyond routine on-site visits. Section 5.18.3 defines centralized monitoring as a remote evaluation of accumulating data, performed in a timely manner by appropriately qualified and trained staff (e.g. data managers, biostatisticians). Sponsors may use on-site-only, a combination of on-site and centralized monitoring, or, where justified, centralized monitoring alone — provided the choice and its rationale are documented in the monitoring plan.
• Updated language on electronic records and essential documents to better accommodate electronic data capture, electronic signatures, and computerized systems, reflecting how far trial conduct had already moved from paper-only processes by 2016.

These changes are what industry shorthand means by “risk-based monitoring became part of GCP” — the concept existed in FDA’s own 2013 risk-based monitoring guidance for industry beforehand, but E6(R2) is what wrote it into the ICH GCP text itself.

How E6(R2) differs from E6(R3)

The two are related by lineage, not interchangeable. See the full ICH E6(R3) entry for its own adoption timeline and complete detail; in summary, relative to E6(R2):

• Structure. E6(R2) is an addendum bolted onto the 1996 E6(R1) text — you read E6(R1) and E6(R2) together as one document. E6(R3) is a full restructuring: a short set of overarching Principles, plus Annex 1 (traditional interventional trials, carrying most of the operational detail E6(R2) contained) and Annex 2 (decentralized, hybrid, and pragmatic trial designs — a category E6(R2) does not address at all).
• Investigational product oversight. E6(R2) places this at Section 5.14, framed as a sponsor-facing section. E6(R3) restates the same responsibility at Section 2.10.1, framed around investigator accountability for handling, dispensing, administration, and return, with specific activities delegable.
• Risk framing. E6(R2) introduced risk-based quality management as an available approach (sponsors may use centralized or risk-proportionate monitoring). E6(R3) goes further, tying requirements like continuing-review frequency to the trial’s documented risk profile as the default expectation, not an optional alternative to a fixed annual cycle.
• Technology and decentralized trials. E6(R2) accommodates electronic records but was written before decentralized trial elements — remote visits, electronic informed consent, direct-to-participant investigational product shipment, wearable/sensor data — were common. E6(R3) Annex 2 addresses these directly; E6(R2) is silent on them.
• Terminology. E6(R3) uses “participant” more consistently in place of “subject” and allows appropriately delegated, trained site staff (not only the investigator) to conduct informed consent discussions.

Which trials and institutions still operate under E6(R2)

E6(R3)’s finalization does not retroactively convert every existing SOP, protocol, or already-authorized trial to the new text. In practice, E6(R2) remains the applicable standard in several overlapping situations:

• Jurisdictions that have not adopted E6(R3). ICH guidelines only take domestic legal or regulatory effect once a member region formally adopts them. In the EU, UK, and Switzerland, E6(R3) Principles and Annex 1 have applied since 23 July 2025 — but any ICH member or observer country that has not separately adopted E6(R3) continues to reference E6(R2) as current.
• FDA-regulated trials in the US, for many purposes. The FDA issued final E6(R3) guidance for industry in September 2025, but FDA guidance documents describe the agency’s current thinking and recommendations rather than binding legal requirements, and the FDA’s E6(R2) guidance (finalized March 2018) has not been withdrawn. Sponsors and sites running US trials should confirm directly which version a given FOA, protocol, or FDA division expects rather than assuming E6(R3) has displaced E6(R2) as a matter of US regulation.
• Trials already underway when E6(R3) took effect. A trial authorized, monitored, and documented under E6(R2)-based SOPs is not automatically out of compliance because a newer guideline exists elsewhere; regulators’ own transition guidance (where issued) governs whether and when an ongoing trial must move to the new text, and many institutions reasonably continue an already-running trial under the version it was designed against.
• Institutions mid-transition. Updating continuing-review SOPs, delegation logs, monitoring plans, and GCP training curricula to reflect E6(R3) is real work, not a document swap. Many institutions are running E6(R2)-based SOPs for existing trials while phasing in E6(R3)-based templates for newly initiated ones.

For any of these situations, treat E6(R2) as fully valid, current GCP text for the trial or jurisdiction it applies to — not as an obsolete document superseded everywhere the moment E6(R3) existed.

Worked examples

Example 1 (illustrative). An academic medical center in the US enrolled a multi-year oncology trial in 2022 under E6(R2)-based SOPs, with a monitoring plan documenting a combination of on-site and centralized monitoring per Section 5.18. In 2026, with E6(R3) Annex 1 now the effective EU standard but only FDA (non-binding) guidance in the US, the site continues to operate that trial under its existing E6(R2) monitoring plan, while its research office begins drafting E6(R3)-aligned templates for trials being newly designed.

Example 2 (illustrative). A CRO conducting essential-document (Trial Master File) reviews for a legacy trial still cites ICH E6(R2) Section 8 as the governing definition of essential documents for that trial, since the trial was authorized before the sponsor’s institution adopted E6(R3)-based document-management SOPs.

Counter-example. A sponsor’s 2026 training slide describes centralized monitoring and quality tolerance limits as “new in E6(R3).” Both actually originated in the 2016 E6(R2) addendum (Sections 5.0 and 5.18); E6(R3) reinforces and generalizes risk-based quality management rather than introducing the concept for the first time. Attributing these to E6(R3) alone is a common, checkable error in institutional training material.

Related CASRAI resources

See also ICH E6(R3) for the current revision and its staged adoption timeline, ICH GCP and ICH (International Council for Harmonisation) for the broader framework, risk-based monitoring (RBM) for the monitoring methodology E6(R2) formalized, Contract Research Organization (CRO) and Clinical Research Associate (CRA) for related roles, the GCP certification guide, What Is a Clinical Trial?, and the Clinical Research Administration pillar page.

References

• ICH, “E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)” — Step 4 final guideline, 9 November 2016 (database.ich.org)
• US FDA / Federal Register, “E6(R2) Good Clinical Practice: Integrated Addendum to E6(R1); International Council for Harmonisation; Guidance for Industry; Availability,” notice of final guidance, 1 March 2018 (federalregister.gov; hhs.gov guidance portal)
• European Medicines Agency, ICH E6(R2) Step 5 guideline PDF (ema.europa.eu)
• FDA, “Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring: Guidance for Industry,” final guidance, 7 August 2013
• See the ICH E6(R3) entry on this site for E6(R3)’s own primary-source references and adoption timeline